Metraipolis › archive › dc_d1bebc04e170
EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy — Europe PMC PMID:42797354
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42797354
- DOI
- 10.3390/pharmaceutics18091179
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T03:49:32.059Z
- SHA-256 of the archived text
e38852a76b979a34c762e50118e490b1375026ecb6a5fa1efe493ce9616bf0e3- Stable URL of this page
https://metraipolis.com/documento/dc_d1bebc04e170
How to cite
EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy — Europe PMC PMID:42797354 — Europe PMC (en), https://europepmc.org/article/MED/42797354 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d1bebc04e170 (Metraipolis archive dc_d1bebc04e170, sha256 e38852a76b979a34c762e50118e490b1375026ecb6a5fa1efe493ce9616bf0e3)
BibTeX
@misc{dcd1bebc04e170,
title = {EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy — Europe PMC PMID:42797354},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42797354},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d1bebc04e170; sha256 e38852a76b979a34c762e50118e490b1375026ecb6a5fa1efe493ce9616bf0e3},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42797354. Agents can read the archived copy with the MCP tool read_document.